If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
162
results.
Updated on
01/09/2024 [06:58:00]
Results 75 to 100 of 162
Absstract of: CN118542847A
本发明公开了一种利用细菌耐药性来反击细菌的“四位一体”纳米颗粒及其在细菌感染的识别和抗菌治疗中的应用。本发明提供的抗菌纳米颗粒由抗生素、金属离子和光敏剂自组装形成。所述纳米颗粒的制备方法，包括如下步骤：将抗生素与金属盐在水中混合，形成抗生素‑金属离子纳米络合物；将含有光敏剂的溶液在搅拌条件下滴加到所述抗生素‑金属离子纳米络合物的悬浊液中，得到所述的抗菌纳米颗粒。本发明所制备的纳米颗粒集合了光动力抗菌、化学动力抗菌、降低细菌谷胱甘肽和抗生素抗菌等功能于一体；其抗菌活性及其荧光性能可被细菌的耐药酶所启动，实现针对细菌或耐药菌感染的特异性抗菌治疗和荧光识别；并显著促进细菌感染伤口的愈合。
Absstract of: CA3226651A1
Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided a method of preparing a formulation comprising GalNAc-lipid nanoparticles, wherein the nanoparticles comprise (i) one or more nucleic acid active agents, (ii) one or more lipid excipients selected from sterol or a derivative thereof, a phospholipid, a stealth lipid, and an amino lipid, and (iii) a GalNAc-lipid receptor targeting conjugate.
Absstract of: FR3145867A1
L’invention a trait au domaine des compositions vaccinales. Elle concerne plus particulièrement une composition vaccinale prophylactique à destination des mammifères et des oiseaux comprenant une bactérie entière tuée, ladite bactérie étant recouverte d’un agent cationique, en particulier des nanoparticules cationiques.
Absstract of: FR3145866A1
L’invention a trait au domaine des compositions vaccinales. Elle concerne plus particulièrement une composition vaccinale prophylactique à destination des mammifères et des oiseaux comprenant une bactérie entière tuée, ladite bactérie étant recouverte d’un agent cationique, en particulier des nanoparticules cationiques.
Absstract of: US2024189340A1
Disclosed herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic acids (e.g., circular polynucleotides), both in vitro and in vivo.
Absstract of: CN118526471A
本发明提供了一种双靶向纳米颗粒及其制备方法和应用，属于药物制剂技术领域。本发明所述的双靶向纳米颗粒包括褐变诱导剂西格列他钠、光热试剂吲哚菁绿、脂肪细胞归巢肽、细胞穿透肽、DSPE‑PEG聚合物、脂质基质。本发明通过将褐变诱导剂和光热试剂封装在生物相容性优良的纳米颗粒中，表面包裹功能化脂肪归巢肽和细胞穿膜肽，构建了双靶向纳米颗粒，结合光热‑药物疗法，可有效促进白色脂肪的“褐变”，改善体重及糖脂代谢，为开发安全有效抗肥胖和相关代谢紊乱的药物奠定基础。
Absstract of: CN118526468A
本发明提供了一种基于疏水作用的负载核酸的脂质体纳米颗粒及其制备方法。本发明使用锚定链将目的核酸和修饰了疏水基团的互补单链进行连接，制备成脂质体纳米颗粒后，可以降低核酸酶对目的核酸的降解，实现目的核酸链的稳定递送。此外，该方法还减少了或避免了阳离子脂质的使用，降低了阳离子脂质体的细胞毒性和副作用。
Absstract of: CN118526469A
本发明涉及一种制备mRNA‑脂质纳米颗粒的优化微流控混合方法，包括配制复方脂质‑乙醇溶液；按N/P＝8，水相：有机相为4:1的流速比，总流速为12ml/min的参数，以及0.75×PBS的条件得到mRNA‑脂质纳米颗粒。本发明通过对探索得到的优化条件进行组合有效的提升了LNPs的递送效率，可应用至mRNA疫苗的制备过程当中。
Absstract of: CN118526470A
本发明涉及一种负载穿心莲内酯的靶向纳米载药系统及其制备方法与应用。包括步骤如下：(1)将聚乳酸羟基乙酸共聚物‑聚乙二醇和穿心莲内酯加入至丙酮中，超声溶解后过滤，得到油相O；(2)将焦磷酸硫胺素加入至PBS缓冲液中，继续向焦磷酸硫胺素溶液中添加岩藻多糖，得到水相W；(3)将油相O注入水相W中，乳化搅拌，再经过滤、超滤、离心、洗涤和干燥后，得到负载穿心莲内酯的靶向纳米载药系统。本发明提供的负载穿心莲内酯的靶向纳米载药系统利用岩藻多糖与巨噬细胞表面受体结合作用，有效提高炎症部位穿心莲内酯的浓度，延长半衰期，使药物作用更加显著，从而达到增强穿心莲内酯抗炎症功能的目的。
Absstract of: CN118526601A
本发明公开了一种用于提高核酸药物递送效率的含N‑氧化三级胺聚合物与核酸药物的偶联物及其纳米颗粒，将含N‑氧化三级胺基团的聚合物偶联到核酸药物链上，制备了它们的偶联物。该偶联物优点是可以入胞直接应用，也可以与阳离子的脂质或聚合物组装，形成由核酸药物/阳离子的脂质或聚合物复合形成的致密内核、外面由含N‑氧化三级胺基团的聚合物形成的电中性聚合物外壳的复合物纳米颗粒。本发明能够应用于体内外高效递送核酸药物，显著降低阳离子脂质带来的毒副作用。
Absstract of: CN118530452A
本申请公开了一种活性氧清除抗炎材料的制备及应用。该活性氧清除抗炎材料的化学结构为#imgabs0#该活性氧清除抗炎材料能够实现多种活性氧(包括双氧水、次氯酸根、超氧阴离子和羟自由基)的有效清除，可用于制备治疗炎症或氧化应激损伤相关疾病的药物。
Absstract of: CN118526584A
本发明公开了一种癌细胞膜修饰的纳米粒子及其制备方法和应用，属于药物制剂领域，癌细胞膜修饰的纳米粒子的制备方法为：(1)在冰浴超声条件下，将溶于有机溶剂的有机染料IR‑1048和溶于冰醋酸的免疫佐剂R837加入至两亲性聚合物F127水溶液中，得到胶束分散液，胶束分散液经透析、冷冻干燥后，得到F127包裹IR1048和R837的纳米粒子FRI；(2)纳米粒子FRI与癌细胞膜共挤出后得到癌细胞膜修饰的纳米粒子CFRI。当CFRI用于癌症治疗时，NIR‑Ⅱ光热剂IR1048与免疫佐剂R837发挥协同作用，实现抗肿瘤的效果。
Absstract of: CN118531068A
本发明公开一种特异性靶向杀伤肝癌细胞的负载紫杉醇的工程化载药囊泡的制备及其应用。所述工程化载药囊泡的制备方法为：制备过表达CD9‑linker‑FTH1‑linker‑IFN‑γ融合蛋白基因的CHO稳转细胞株；将CHO稳转细胞株重悬于完全培养基中进行培养；当细胞融合度达到80％时，使用胰酶消化贴壁细胞并重悬于无血清DMEM培养液中，紫外照射，加入紫杉醇，共培养24h；培养结束后，采用梯度离心法收取细胞膜囊泡，即得特异性靶向杀伤肝癌细胞的负载紫杉醇的工程化载药囊泡。本发明制备的负载紫杉醇的工程化载药囊泡具有特异性识别和杀伤肝癌细胞的特点，在小鼠体内取得了较为理想的疗效。该工程化载药囊泡为化疗药物输送载体的选择上提供了新的方法，为临床上肝癌的治疗手段提供新的策略。
Absstract of: US2024277867A1
Provided is a system for drug delivery comprising a modified poly (amidoamine) (“PAMAM”) comprising a photo-cleavable compound bound to one or more active agents to form a nanocomplex. Also provided is a method of treating a subject comprising administering the PAMAM nanocomplex and irradiating the nanocomplex at the target site with a light source. In particular, the modified PAMAM is a DEACM-modified PAMAM or a BODIPY-modified PAMAM. Also provided is a method for screening for PAMAM-coumarin-active agent nanocomplexes.
Absstract of: US2024277848A1
Provided are a surface-modified nanoparticle that can be easily produced and can selectively deliver boron atoms into cancer cells and maintain the boron atoms, and a method for producing the surface-modified nanoparticle. The surface-modified nanoparticle of the present disclosure includes a nanocarbon material, and a surface-modifying group of the nanocarbon material, and has a group containing a boron atom as the surface-modifying group.
Absstract of: US2024277866A1
The invention relates to new calibrated-size gas-filled microvesicles bearing an overall positive charge, to their use and to their method of manufacturing. The gas-filled microvesicles have a geometric standard deviation (GSD) value of at least 1.25 or lower and a stabilizing envelope comprising an amphiphilic material, said amphiphilic material comprising a cationic lipid and a neutral or cationic amphiphilic polymeric compound.
Absstract of: US2024277751A1
This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject. In particular, the present invention is directed to crystalline polymorphic forms (e.g. coordinate polymeric forms) of STING agonists associated (e.g. mixed) with one or more metal ions (e.g., Zn2+, Mn2+, Al3+, Fe3+, Cu2+), as well as systems and methods utilizing such compositions (e.g., in therapeutic settings).
Absstract of: US2024277759A1
Provided is an antibacterial composition containing transition metal dichalcogenide (TMD) as an active ingredient and a method comprising: adding bulk TMD to a polyacrylic acid (PAA) solution to prepare a mixed solution; ultrasonically treating the mixed solution; centrifuging the ultrasonically treated mixed solution to obtain a precipitate from a supernatant; and redispersing the precipitate in water and centrifuging the same to obtain a PAA-TMD nanosheet from the supernatant.
Absstract of: US2024277753A1
Darbepoetin alpha treats anemia and it is traditionally manufactured using recombinant Chinese Hamster Ovary cells, a complex and expensive process; this invention reports an mRNA composition that encodes darbepoetin alpha in vivo as a therapeutic protein.
Absstract of: US2024277833A1
The application describes methods and compositions comprising ceDNA vectors useful for the expression of antigens and immunogenic peptides in a cell, tissue or subject, and methods of treatment and/or prevention of various infectious diseases, autoimmune disorders and cancers.
Absstract of: US2024277821A1
A method of targeting antigen-presenting cells and delivering an encapsulated payload with lipid nanoparticles including a POZ-lipid conjugate. The encapsulated payload may include, but is not limited to, a nucleic acid payload such as mRNA or modified mRNA. These LNPs are not subject to accelerated blood clearance and they have a low or reduced immunogenicity profile in vivo.
Absstract of: US2024277818A1
A composition can comprise a metal-organic framework (MOF) nanoparticle for oral protein administration, wherein the MOF comprises a nano-scale acid-resistant MOF; a small molecular protein/polypeptide drug and a targeting molecule, wherein the MOF is loaded with the small molecular protein/polypeptide; and targeting molecules, wherein a surface of the MOF is coated with the targeting molecules.
Absstract of: US2024277746A1
Provided is a pharmaceutical solid-in-oil nano-dispersion composition that may include ascorbic acid or a astable derivative thereof, a surfactant coating the ascorbic acid or its derivative and an oil vehicle, wherein the ascorbic acid or its derivative are uniformly dispersed in the solid-in-oil nano-dispersion composition. In addition to that, the present disclosure provides a method of preparing the solid-in-oil nano-dispersion composition and formulations thereof. Also, after administration the S/O nano-dispersion based dosage form to subject, it will improve the corneal epithelial wounds healing.
Absstract of: US2024277656A1
Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
Nº publicación: US2024277642A1 22/08/2024
Applicant:
UNIV OF TSUKUBA [JP]
UNIVERSITY OF TSUKUBA
Absstract of: US2024277642A1
Provided is a valproic acid derivative for improving disadvantages or defects accompanying when valproic acid itself or the like is used as a medicine. Provided is a block copolymer which is a polymerized product of valproic acid and comprises a poly(ethylene glycol) segment and a poly(vinyl valproate) segment.
BOPI
Electronic site
